SCHEMBL3944324

SCHEMBL3944324

COc1ccc(C)cc1NC(=O)Nc1ccc2nc(Nc3ncnc4cc(OCC5CCN(C)CC5)c(OC)cc34)sc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.61
EGFR P00533 16/20 0.58
FGFR1 P11362 2/20 0.58
FLT1 P17948 2/20 0.58
FLT4 P35916 2/20 0.58
SRC P12931 2/20 0.51
BMPR1B O00238 1/20 0.51
PLK4 O00444 1/20 0.51
CIT O14578 1/20 0.51
GAK O14976 1/20 0.51
EPHB6 O15197 1/20 0.51
RIPK2 O43353 1/20 0.51
ROCK2 O75116 1/20 0.51
STK10 O94804 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
ERBB2 P04626 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
CSF1R P07333 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3948811 0.89 KDR (0.60) KDREGFRFLT4ERBB2PDGFRB
SCHEMBL3948294 0.88 EGFR (0.65) KDREGFRFLT4ERBB2PDGFRB
SCHEMBL3945407 0.88 KDR (0.54) KDREGFRKIT
SCHEMBL3948584 0.86 KDR (0.58) KDREGFRFLT1FLT4
SCHEMBL3951156 0.85 EGFR (0.62) KDREGFRSRCROCK2LCK
SCHEMBL3946971 0.85 EGFR (0.67) KDREGFRSRCROCK2LCK
SCHEMBL3951600 0.84 KDR (0.49) KDREGFRERBB2RETMAPK14
SCHEMBL4590707 0.84 KDR (0.46) KDREGFRFGFR1FLT1FLT4
SCHEMBL3951047 0.83 EGFR (0.49) KDREGFRERBB2RETKIF5B
4Sc-203 SCHEMBL1505017 0.83 EGFR (0.64) KDREGFRFLT4ERBB2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
EP-1885719-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2008-02-13 EP disclosed
WO-2006066795-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-06-29 WO disclosed
US-20060135782-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135782-A1 Benzazole analogues and uses thereof DCK, SBK3, DAPK3 KDR 1657/4885EGFR 437/4885FGFR1 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.